Obinutuzumab Biosimilar – Research Grade
- Sizes: 0.1mg, 5mg, 10mg, 20mg, 50mg
- Category: ichorbio, Low endotoxin, biosimilar antibody
- Target: CD20
- Clone:
- Host: Humanized
-
Datasheet Tech Support
PRODUCT DETAILS
SPECIFICATIONS |
|
---|---|
PRODUCT NAME |
Obinutuzumab Biosimilar - Research Grade |
SPECIES REACTIVITY |
Human |
HOST |
Humanized |
SPECIFICITY |
Detects human CD20. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Obinutuzumab/afutuzumab. This product is for research use only. |
PURIFICATION METHOD |
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. |
ANTIGEN DISTRIBUTION |
|
IMMUNOGEN |
|
CONCENTRATION |
|
FORMULATION |
Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free. |
PURITY |
>95% by SDS-PAGE and HPLC |
ENDOTOXIN |
≤ 0.75 EU/mg as determined by the LAL method |
AGGRIGATION |
|
STORAGE CONDITION |
Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles. |
TARGET |
|
---|---|
TARGET |
CD20 |
CLONE |
|
SYNONYMS |
|
BACKGROUND |
Obinutuzumab biosimilar is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells. The molecular mass of the antibody is approximately 150 kDa. it is produced by mammalian cell (CHO) suspension culture. It was engineered for reduced fucose content as compared to a typical IgG1 produced in CHO cells. |
UNIPROT |
|
PATHOGEN TEST |
|
APPLICATIONS |
|
APPLICATION NOTES |
|
USAGE |
Products are for research use only. Not for use in diagnostic or therapeutic procedures. |